Lentiviral vectors in gene therapy: their current status and future potential
- PMID: 20143172
- PMCID: PMC2837622
- DOI: 10.1007/s00005-010-0063-4
Lentiviral vectors in gene therapy: their current status and future potential
Abstract
The concept of gene therapy originated in the mid twentieth century and was perceived as a revolutionary technology with the promise to cure almost any disease of which the molecular basis was understood. Since then, several gene vectors have been developed and the feasibility of gene therapy has been shown in many animal models of human disease. However, clinical efficacy could not be demonstrated until the beginning of the new century in a small-scale clinical trial curing an otherwise fatal immunodeficiency disorder in children. This first success, achieved after retroviral therapy, was later overshadowed by the occurrence of vector-related leukemia in a significant number of the treated children, demonstrating that the future success of gene therapy depends on our understanding of vector biology. This has led to the development of later-generation vectors with improved efficiency, specificity, and safety. Amongst these are HIV-1 lentivirus-based vectors (lentivectors), which are being increasingly used in basic and applied research. Human gene therapy clinical trials are currently underway using lentivectors in a wide range of human diseases. The intention of this review is to describe the main scientific steps leading to the engineering of HIV-1 lentiviral vectors and place them in the context of current human gene therapy.
Figures


Similar articles
-
Strategies for retargeted gene delivery using vectors derived from lentiviruses.Curr Gene Ther. 2004 Dec;4(4):427-43. doi: 10.2174/1566523043345995. Curr Gene Ther. 2004. PMID: 15578992 Review.
-
Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection.Curr HIV Res. 2004 Apr;2(2):185-91. doi: 10.2174/1570162043484906. Curr HIV Res. 2004. PMID: 15078182 Review.
-
Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective.Hum Gene Ther. 2015 May;26(5):257-65. doi: 10.1089/hum.2015.025. Epub 2015 Apr 20. Hum Gene Ther. 2015. PMID: 25807962 Free PMC article. Review.
-
Clinical use of lentiviral vectors.Leukemia. 2018 Jul;32(7):1529-1541. doi: 10.1038/s41375-018-0106-0. Epub 2018 Mar 22. Leukemia. 2018. PMID: 29654266 Free PMC article. Review.
-
The molecular genetics of lentiviral vectors--current and future perspectives.Curr Gene Ther. 2001 Sep;1(3):237-51. doi: 10.2174/1566523013348634. Curr Gene Ther. 2001. PMID: 12109139
Cited by
-
Restoration of Thymus Function with Bioengineered Thymus Organoids.Curr Stem Cell Rep. 2016 Jun;2(2):128-139. doi: 10.1007/s40778-016-0040-x. Curr Stem Cell Rep. 2016. PMID: 27529056 Free PMC article.
-
Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's Disease.Yale J Biol Med. 2016 Jun 27;89(2):215-25. eCollection 2016 Jun. Yale J Biol Med. 2016. PMID: 27354847 Free PMC article. Review.
-
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.Oncoimmunology. 2014 Jul 3;3(7):e945378. doi: 10.4161/21624011.2014.945378. eCollection 2014. Oncoimmunology. 2014. PMID: 25954597 Free PMC article.
-
Effective In Vivo Gene Modification in Mouse Tissue-Resident Peritoneal Macrophages by Intraperitoneal Delivery of Lentiviral Vectors.Mol Ther Methods Clin Dev. 2019 Oct 18;16:21-31. doi: 10.1016/j.omtm.2019.10.004. eCollection 2020 Mar 13. Mol Ther Methods Clin Dev. 2019. PMID: 31720306 Free PMC article.
-
The 18 kDa Translocator Protein (TSPO) Overexpression in Hippocampal Dentate Gyrus Elicits Anxiolytic-Like Effects in a Mouse Model of Post-traumatic Stress Disorder.Front Pharmacol. 2018 Nov 23;9:1364. doi: 10.3389/fphar.2018.01364. eCollection 2018. Front Pharmacol. 2018. PMID: 30532709 Free PMC article.
References
-
- Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, Takahashi T, Ikawa M, Okabe M, Inoue N, Okamoto-Tanaka M, Ishizaki H, Miyoshi J, Matsumoto M, Seya T. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A. 2007a;104:252–7. - PMC - PubMed
-
- Akazawa T, Shingai M, Sasai M, Ebihara T, Inoue N, Matsumoto M, Seya T. Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. FEBS Lett. 2007b;581:3334–40. - PubMed
-
- Anderson WF, Blaese RM, Culver K. The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. Hum Gene Ther. 1990;1:331–62. - PubMed
-
- Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP, Thrasher AJ, Collins MK, Philpott NJ. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther. 2007;15:1947–54. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical